Dangerous Drugs & Devices | MattLaw™
Different Involvement of OAT in Renal Disposition of Oral Anticoagulants Rivaroxaban, Dabigatran, and Apixaban - Journal of Pharmaceutical Sciences
Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study | Scientific Reports
Office of Clinical Parmacology Review (XARELTO)
Pradaxa And Xarelto: Top Heart Doctors Concerned Over New Blood Thinners | HuffPost Life
Management guideline for bleeding while taking dabigatran, rivaroxaban... | Download Scientific Diagram
Pharmaceutics | Free Full-Text | The Development and Optimization of Hot-Melt Extruded Amorphous Solid Dispersions Containing Rivaroxaban in Combination with Polymers
Assessment of Dose Proportionality of Rivaroxaban Nanocrystals | SpringerLink
Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study | Thrombosis Journal | Full Text
Different Involvement of OAT in Renal Disposition of Oral Anticoagulants Rivaroxaban, Dabigatran, and Apixaban
Eliquis vs. Xarelto: Differences, similarities, and which is better for you
Office of Clinical Parmacology Review (XARELTO)
Office of Clinical Parmacology Review (XARELTO)
Office of Clinical Parmacology Review (XARELTO)
Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study | Thrombosis Journal | Full Text
Therapeutic Monitoring of Rivaroxaban in Dogs Using Thromboelastography and Prothrombin Time
Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation - Clinical Therapeutics
Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020 | SpringerLink
Insight: Top heart doctors fret over new blood thinners | Reuters
Prescription Drugs Manufactured By Janssen Pharmaceuticals, Inc. - Recall Guide
Study design of GENERAL (general practitioners and embolism prevention in NVAF patients treated with rivaroxaban: Real-life evidence): A multicenter prospective cohort study in primary care physicians to investigate the effectiveness and safety
